Ajinomoto Co., Inc. used data from CGT Catapult’s Industrialisation group work on pluripotent stem cell process and manufacturing development, highlighting global reach of Catapult programmes, and appetite from globally significant organisations in British-led cell and gene therapy industry.
The Cell and Gene Therapy Catapult (CGT Catapult) today announced it has licensed data from its pluripotent stem cell development programme ‘Cell Plasticity' to Japanese food and amino acid company Ajinomoto Co., Inc. (Ajinomoto Co.), further advancing CGT Catapult’s place as one of the global leaders in the development of solutions for the industrialisation of cell therapies. Through the use of process and analytical data from CGT Catapult’s programme, Ajinomoto Co. was able to evaluate the adherent expansion of CGT’s human induced pluripotent stem cell (iPSC) line CGT-RCiB10 in different culture systems.
CGT Catapult is dedicated to supporting the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation. As part of this, CGT Catapult has been working to develop scalable processing platforms of pluripotent stem cells and their derivatives, and therefore support the translation of research into commercially viable advanced therapy medicinal products. The continued focus from CGT on developing novel products, such as the pluripotent stem cell programme, provides the organisation with the opportunity to collaborate with academic and commercial partners across the world in some of the most innovative and promising areas of medical research.
We are thrilled that our research continues to be sought after by organisations across the globe. The licensing of this data to Ajinomoto Co. highlights the benefit and skills we continue to bring to these organisations, and through them, how the Catapult is able to contribute to the advancement of technologies and medicines of the future.
Keith Thompson, Chief Executive Officer